Document is current
Any future updates will be listed below
-
Authors
MacDonald, Grace
Sitlinger, Andrea
Deal, Michael A.
Hanson, Erik D.
Ferraro, Stephanie
Pieper, Carl F.
Weinberg, J. Brice
Brander, Danielle M.
Bartlett, David B.
-
Funding
Funding for this research was provided by:
American Society of Hematology
National Institutes of Health (T32HL007057, P30-AG028716)
U.S. Department of Veterans Affairs
- License Information
-
More Information
Article History
Received: 30 August 2021
Accepted: 8 November 2021
First Online: 30 November 2021
Competing interests
: D.M.B. has been a consultant, scientific advisory board member, and site clinical trial Principal Investigator (PI) (grant paid to institution) for AbbVie, Genentech, and Verastem; scientific advisory board member and site clinical trial PI (grant paid to institution) for ArQule and TG Therapeutics; site clinical trial PI (grant paid to institution) for Ascentage, BeiGene, DTRM, Juno/Celgene/BMS, MEI Pharma, and Tolero; consultant and site clinical trial PI (grant paid to institution) for AstraZeneca and Pharmacyclics; consultant and scientific advisory board member for Pfizer; consultant for Teva; National Comprehensive Cancer Network panel member; and has participated in the informCLL registry steering committee (AbbVie), REAL registry steering committee (Verastem), and Biosimilars outcomes research panel (Pfizer). The remaining authors declare no competing financial interests.
